Shots: The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with […]readmore
Tags : study
Shots: The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD The two P-III study resulted in meeting 1EPs @16 wks. with […]readmore
Shots: Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial The focus of the agreement is for the onset […]readmore
Shots: The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE, presented at European Congress of Rheumatology 2018 Lilly is also evaluating baricitinib’s two doses in […]readmore